Intermittent androgen suppression for rising PSA level after radiotherapy.

BACKGROUND Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous androgen deprivation in a noninferiority randomized trial. METHODS We enrolled patients with a PSA level greater than 3 ng per milliliter more than 1 year after primary or salvage radiotherapy for localized prostate cancer. Intermittent treatment was provided in 8-month cycles, with nontreatment periods determined according to the PSA level. The primary end point was overall survival. Secondary end points included quality of life, time to castration-resistant disease, and duration of nontreatment intervals. RESULTS Of 1386 enrolled patients, 690 were randomly assigned to intermittent therapy and 696 to continuous therapy. Median follow-up was 6.9 years. There were no significant between-group differences in adverse events. In the intermittent-therapy group, full testosterone recovery occurred in 35% of patients, and testosterone recovery to the trial-entry threshold occurred in 79%. Intermittent therapy provided potential benefits with respect to physical function, fatigue, urinary problems, hot flashes, libido, and erectile function. There were 268 deaths in the intermittent-therapy group and 256 in the continuous-therapy group. Median overall survival was 8.8 years in the intermittent-therapy group versus 9.1 years in the continuous-therapy group (hazard ratio for death, 1.02; 95% confidence interval, 0.86 to 1.21). The estimated 7-year cumulative rates of disease-related death were 18% and 15% in the two groups, respectively (P=0.24). CONCLUSIONS Intermittent androgen deprivation was noninferior to continuous therapy with respect to overall survival. Some quality-of-life factors improved with intermittent therapy. (Funded by the Canadian Cancer Society Research Institute and others; ClinicalTrials.gov number, NCT00003653.).

[1]  J. Crook,et al.  Intermittent androgen suppression in the management of prostate cancer. , 1999, Urology.

[2]  P. Macaskill,et al.  Stopping rules for clinical trials incorporating clinical opinion. , 1984, Biometrics.

[3]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Theyer,et al.  Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. , 1997, British Journal of Cancer.

[5]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[6]  Goldenberg,et al.  Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up. , 1999, Molecular urology.

[7]  M. Blute,et al.  Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. , 2005, The Journal of urology.

[8]  R. Gardiner,et al.  Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial , 2002, BJU international.

[9]  P. Scardino,et al.  Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. , 2009, European urology.

[10]  P. Scardino,et al.  Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. , 2012, European urology.

[11]  A. D'Amico,et al.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Prince,et al.  Long‐term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33‐month observational study , 2009, BJU international.

[14]  M. Maggio,et al.  Endocrine complications of androgen-deprivation therapy in men with prostate cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[15]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[16]  C. Lawton.  Ten-Year Follow-up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer , 2009 .

[17]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[18]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[19]  A. Kibel.  Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer , 2007 .

[20]  C. Tangen,et al.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. , 2004, Urology.

[21]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[22]  U. Tunn.  Intermittent endocrine therapy of prostate cancer. , 1996, European urology.

[23]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[24]  J. Moul,et al.  Prostate specific antigen recurrence after definitive therapy. , 2007, The Journal of urology.

[25]  G. Williams,et al.  Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. , 1997, Urology.

[26]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[27]  A R Willan,et al.  Power function arguments in support of an alternative approach for analyzing management trials. , 1994, Controlled clinical trials.

[28]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. , 2000, Molecular urology.

[29]  C. Higano,et al.  The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. , 2003, The Journal of urology.

[30]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[31]  M. Gleave,et al.  Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  W. Ellis,et al.  Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. , 1996, Urology.

[33]  P. Scardino,et al.  Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[34]  D. Dearnaley,et al.  A pilot study of intermittent androgen deprivation in advanced prostate cancer. , 1998, British journal of urology.

[35]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[36]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.